NCT07174830 - Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 16, 2026

Conditions

Healthy Participants

Interventions

DRUG

Allisartan Isoproxil Tablets 240mg or placebo

Allisartan Isoproxil Tablets 240mg or placebo, QD

DRUG

Allisartan Isoproxil Tablets 480mg or placebo

Allisartan Isoproxil Tablets 480mg or placebo, QD

DRUG

Allisartan Isoproxil Tablets 720mg or placebo

Allisartan Isoproxil Tablets 720mg or placebo, QD

Trial Locations (1)

RECRUITING

Shenzhen People's Hospital, Shenzhen

All Listed Sponsors

lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY